Protective effect of betulin against aluminium-induced Alzheimer-like neurodegeneration

IF 0.4 4区医学 Q4 PHARMACOLOGY & PHARMACY

Acta poloniae pharmaceutica Pub Date : 2023-04-28 DOI:10.32383/appdr/161588

A. Zakrzeska, P. Kitlas, A. Shlyahtun, Ryszard Jabłoński, M. Tomulewicz, Natalia Szymańska

{"title":"Protective effect of betulin against aluminium-induced Alzheimer-like neurodegeneration","authors":"A. Zakrzeska, P. Kitlas, A. Shlyahtun, Ryszard Jabłoński, M. Tomulewicz, Natalia Szymańska","doi":"10.32383/appdr/161588","DOIUrl":null,"url":null,"abstract":"The purpose of this study was to show the preventive properties of the botulin (Bet) and its combination with cyclodextrin in a model of neurodegenerative disease like Alzheimer's disease (AD) in rats. Betulin was obtained from birch bark using standard methodology. The AD model was induced by administering aluminum chloride AlCl3 (200 mg/kg/day) to animals for 120 days. All animals were divided into 4 groups: the control group (sham operation), the second - the AD model (Alz) without prevention with betulin, the third - the Alz+Bet receiving betulin (100 mg/kg/day, i.g., during the last 50% of the experimental days), and the Alz+Bet Complex receiving betulin in complex with cyclodextrin (100 mg/kg/day, i.g., during the last 50% of the experimental days). We showed that betulin in complex with cyclodextrin improve the spatial memory and lowered levels of the TNF-α, APLP2 and β-amyloid in rats with AlCl3-induced AD. We conclude that betulin has neuroprotective properties which may form the basis for the development of a new pharmaceutical that is effective in both the prevention and treatment of Alzheimer's disease.","PeriodicalId":7147,"journal":{"name":"Acta poloniae pharmaceutica","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta poloniae pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32383/appdr/161588","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The purpose of this study was to show the preventive properties of the botulin (Bet) and its combination with cyclodextrin in a model of neurodegenerative disease like Alzheimer's disease (AD) in rats. Betulin was obtained from birch bark using standard methodology. The AD model was induced by administering aluminum chloride AlCl3 (200 mg/kg/day) to animals for 120 days. All animals were divided into 4 groups: the control group (sham operation), the second - the AD model (Alz) without prevention with betulin, the third - the Alz+Bet receiving betulin (100 mg/kg/day, i.g., during the last 50% of the experimental days), and the Alz+Bet Complex receiving betulin in complex with cyclodextrin (100 mg/kg/day, i.g., during the last 50% of the experimental days). We showed that betulin in complex with cyclodextrin improve the spatial memory and lowered levels of the TNF-α, APLP2 and β-amyloid in rats with AlCl3-induced AD. We conclude that betulin has neuroprotective properties which may form the basis for the development of a new pharmaceutical that is effective in both the prevention and treatment of Alzheimer's disease.

查看原文本刊更多论文

槟榔素对铝诱导的阿尔茨海默病样神经退行性变的保护作用

本研究的目的是在大鼠阿尔茨海默病（AD）等神经退行性疾病模型中展示肉毒杆菌素（Bet）及其与环糊精的组合的预防特性。桦木脂蛋白是用标准方法从桦树皮中提取的。通过向动物施用氯化铝AlCl3（200mg/kg/天）达120天来诱导AD模型。将所有动物分为4组：对照组（假手术），第二组-没有用槟榔预防的AD模型（Alz），第三组-接受槟榔的Alz+Bet（100 mg/kg/天，在实验的最后50%内，i.g.），以及接受槟榔与环糊精复合物的Alz+Tet复合物（100 mg/kg/d，i.g.，在实验最后50%内）。我们发现，槟榔与环糊精的复合物可以改善AlCl3诱导的AD大鼠的空间记忆，降低TNF-α、APLP2和β-淀粉样蛋白的水平。我们得出的结论是，槟榔具有神经保护特性，这可能为开发一种有效预防和治疗阿尔茨海默病的新药奠定基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta poloniae pharmaceutica 医学-药学

CiteScore

0.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The international journal of the Polish Pharmaceutical Society is published in 6 issues a year. The journal offers Open Access publication of original research papers, short communications and reviews written in English, in all areas of pharmaceutical sciences. The following areas of pharmaceutical sciences are covered: Analysis, Biopharmacy, Drug Biochemistry, Drug Synthesis, Natural Drugs, Pharmaceutical Technology, Pharmacology and General. A bimonthly appearing in English since 1994, which continues “Acta Poloniae Pharmaceutica”, whose first issue appeared in December 1937. The war halted the activity of the journal’s creators. Issuance of “Acta Poloniae Pharmaceutica” was resumed in 1947. From 1947 the journal appeared irregularly, initially as a quarterly, then a bimonthly. In the years 1963 – 1973 alongside the Polish version appeared the English edition of the journal. Starting from 1974 only works in English are published in the journal. Since 1995 the journal has been appearing very regularly in two-month intervals (six books a year). The journal publishes original works from all fields of pharmacy, summaries of postdoctoral dissertations and laboratory notes.